Associated Papers
TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Kobayashi K
Journal of Clinical Medicine, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients.
Smolenschi C et al.
Npj Precision Oncology, 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study.
Oiki H et al.
Cells, 2025
An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer.
Yu Y et al.
Bmc Pulmonary Medicine, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Inherited rare epidermal growth factor receptor mutation and somatic mutations in patients with non-small cell lung cancer: a case report.
Saridaki Z et al.
Bmc Medical Genomics, 2025
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.
Vasseur D et al.
Molecular Cancer, 2024
Advancing Cancer Care in Colombia: Results of the First In Situ Implementation of Comprehensive Genomic Profiling.
López Rivera JJ et al.
Journal of Personalized Medicine, 2024
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.
Szpechcinski A et al.
International Journal of Molecular Sciences, 2024
A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review.
Sharma P et al.
Clinical Lung Cancer, 2024
Microfluidics-based EGFR mutation detection and its implication in the resource-limited clinical setting.
Joshi P et al.
International Journal of Experimental Pathology, 2024
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK et al.
Nature Communications, 2024
An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report.
Boukansa S et al.
Journal of Medical Case Reports, 2024
Lung cancer in patients who have never smoked - an emerging disease.
LoPiccolo J et al.
Nature Reviews. Clinical Oncology, 2024
Follicular cell-derived thyroid carcinomas harboring novel genetic BRAFNON-V600E mutations: real-world data obtained using a multigene panel.
von Ammon JL et al.
Archives of Endocrinology and Metabolism, 2024
Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.
Slomka J et al.
Plos One, 2024
Susceptibility Genes Associated with Multiple Primary Cancers.
Lu M et al.
Cancers, 2023
Germline EGFR Mutations and Familial Lung Cancer.
Oxnard GR et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2023
The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality.
Farinea G et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2023
EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.
Montella T et al.
Jco Global Oncology, 2023
Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies.
Aktas T et al.
Frontiers in Bioscience (landmark Edition), 2023
Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications.
Hernandez-Martinez JM et al.
Critical Reviews in Oncology/hematology, 2023
NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC.
Mendes C et al.
Lung Cancer (amsterdam, Netherlands), 2023
Actionability classification of variants of unknown significance correlates with functional effect.
Johnson A et al.
Npj Precision Oncology, 2023
Germline EGFR mutations in lung cancer (Review).
Liu M et al.
Oncology Letters, 2023
Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing.
Ahn BC et al.
Cancer Research and Treatment, 2023
Assessment of the Mutation Profile of Tonsillar Squamous Cell Carcinomas Using Targeted Next-Generation Sequencing.
Park HY et al.
Biomedicines, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations.
Kang L et al.
Frontiers in Oncology, 2023
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
The landscape of actionable genomic alterations in lung adenocarcinomas in India.
Sharma R et al.
Frontiers in Genetics, 2023
Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study.
Gu L et al.
Journal of Clinical Medicine, 2022
Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
Pang LL et al.
Cancer, 2022
Multiple mutations in the EGFR gene in lung cancer: a systematic review.
Castañeda-González JP et al.
Translational Lung Cancer Research, 2022
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing.
Nkosi D et al.
Genes, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma.
Chen S et al.
Bmc Genomics, 2022
Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer.
Zhang L et al.
Frontiers in Oncology, 2022
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S et al.
Cancer Medicine, 2021
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Robichaux JP et al.
Nature, 2021